Which has stronger earnings & valuation, TMDX or GKOS?

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 4.39 $190.29M $4.40 17.47 Glaukos $551.35M 15.04 -$187.69M -$3.28 N/A

Does the media favor TMDX or GKOS?

In the previous week, Glaukos had 3 more articles in the media than TransMedics Group. MarketBeat recorded 5 mentions for Glaukos and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.42 beat Glaukos' score of 0.87 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, LQDA or TMDX?

TransMedics Group has higher revenue and earnings than Liquidia. TransMedics Group is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 42.60 -$68.92M $0.14 541.68 TransMedics Group $605.49M 4.39 $190.29M $4.40 17.47

Does the media prefer LQDA or TMDX?

In the previous week, Liquidia had 9 more articles in the media than TransMedics Group. MarketBeat recorded 11 mentions for Liquidia and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.42 beat Liquidia's score of 0.51 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TMDX or STVN?

TransMedics Group presently has a consensus price target of $134.50, suggesting a potential upside of 74.94%. Given TransMedics Group's higher probable upside, equities research analysts clearly believe TransMedics Group is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransMedics Group 0 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.46 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media prefer TMDX or STVN?

In the previous week, Stevanato Group had 2 more articles in the media than TransMedics Group. MarketBeat recorded 4 mentions for Stevanato Group and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.42 beat Stevanato Group's score of 0.65 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LIVN or TMDX?

In the previous week, TransMedics Group had 1 more articles in the media than LivaNova. MarketBeat recorded 2 mentions for TransMedics Group and 1 mentions for LivaNova. TransMedics Group's average media sentiment score of 1.42 beat LivaNova's score of 0.89 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TransMedics Group (TMDX) Competitors

$76.88 -0.73 (-0.94%)

As of 02:11 PM Eastern

Compare

TMDX vs. GKOS, LQDA, BLCO, STVN, and LIVN

Should you buy TransMedics Group stock or one of its competitors? MarketBeat compares TransMedics Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TransMedics Group include Glaukos (GKOS), Liquidia (LQDA), Bausch + Lomb (BLCO), Stevanato Group (STVN), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does TransMedics Group compare to Glaukos?

TransMedics Group (NASDAQ:TMDX) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

TransMedics Group has a net margin of 27.04% compared to Glaukos' net margin of -34.34%. TransMedics Group's return on equity of 22.38% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Glaukos	-34.34%	-6.92%	-5.25%

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 5.9% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Glaukos had 3 more articles in the media than TransMedics Group. MarketBeat recorded 5 mentions for Glaukos and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.42 beat Glaukos' score of 0.87 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group presently has a consensus target price of $134.50, indicating a potential upside of 74.94%. Glaukos has a consensus target price of $149.17, indicating a potential upside of 5.66%. Given TransMedics Group's higher probable upside, equities analysts clearly believe TransMedics Group is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.39	$190.29M	$4.40	17.47
Glaukos	$551.35M	15.04	-$187.69M	-$3.28	N/A

TransMedics Group has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Summary

TransMedics Group beats Glaukos on 12 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to Liquidia?

Liquidia (NASDAQ:LQDA) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Liquidia has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

Liquidia currently has a consensus target price of $67.43, suggesting a potential downside of 11.09%. TransMedics Group has a consensus target price of $134.50, suggesting a potential upside of 74.94%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.90
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

TransMedics Group has a net margin of 27.04% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
TransMedics Group	27.04%	22.38%	8.46%

64.5% of Liquidia shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Liquidia had 9 more articles in the media than TransMedics Group. MarketBeat recorded 11 mentions for Liquidia and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.42 beat Liquidia's score of 0.51 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has higher revenue and earnings than Liquidia. TransMedics Group is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	42.60	-$68.92M	$0.14	541.68
TransMedics Group	$605.49M	4.39	$190.29M	$4.40	17.47

Summary

TransMedics Group beats Liquidia on 10 of the 17 factors compared between the two stocks.

How does TransMedics Group compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Bausch + Lomb presently has a consensus target price of $17.92, suggesting a potential upside of 13.43%. TransMedics Group has a consensus target price of $134.50, suggesting a potential upside of 74.94%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts plainly believe TransMedics Group is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by insiders. Comparatively, 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TransMedics Group has a net margin of 27.04% compared to Bausch + Lomb's net margin of -4.21%. TransMedics Group's return on equity of 22.38% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
TransMedics Group	27.04%	22.38%	8.46%

In the previous week, TransMedics Group had 2 more articles in the media than Bausch + Lomb. MarketBeat recorded 2 mentions for TransMedics Group and 0 mentions for Bausch + Lomb. TransMedics Group's average media sentiment score of 1.42 beat Bausch + Lomb's score of 0.00 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Bausch + Lomb	Neutral
TransMedics Group	Positive

Bausch + Lomb has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

TransMedics Group has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.11	-$360M	-$0.62	N/A
TransMedics Group	$605.49M	4.39	$190.29M	$4.40	17.47

Summary

TransMedics Group beats Bausch + Lomb on 15 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to Stevanato Group?

TransMedics Group (NASDAQ:TMDX) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

TransMedics Group has higher earnings, but lower revenue than Stevanato Group. TransMedics Group is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.39	$190.29M	$4.40	17.47
Stevanato Group	€1.34B	4.03	€158.21M	€0.59	30.29

In the previous week, Stevanato Group had 2 more articles in the media than TransMedics Group. MarketBeat recorded 4 mentions for Stevanato Group and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.42 beat Stevanato Group's score of 0.65 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has a net margin of 27.04% compared to Stevanato Group's net margin of 11.76%. TransMedics Group's return on equity of 22.38% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Stevanato Group	11.76%	10.27%	6.08%

TransMedics Group presently has a consensus price target of $134.50, suggesting a potential upside of 74.94%. Given TransMedics Group's higher probable upside, equities research analysts clearly believe TransMedics Group is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

99.7% of TransMedics Group shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

TransMedics Group has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Summary

TransMedics Group beats Stevanato Group on 12 of the 17 factors compared between the two stocks.

How does TransMedics Group compare to LivaNova?

LivaNova (NASDAQ:LIVN) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

LivaNova presently has a consensus target price of $80.75, suggesting a potential downside of 0.31%. TransMedics Group has a consensus target price of $134.50, suggesting a potential upside of 74.94%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

97.6% of LivaNova shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

TransMedics Group has lower revenue, but higher earnings than LivaNova. TransMedics Group is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.21	-$242.47M	$1.95	41.54
TransMedics Group	$605.49M	4.39	$190.29M	$4.40	17.47

LivaNova has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

In the previous week, TransMedics Group had 1 more articles in the media than LivaNova. MarketBeat recorded 2 mentions for TransMedics Group and 1 mentions for LivaNova. TransMedics Group's average media sentiment score of 1.42 beat LivaNova's score of 0.89 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has a net margin of 27.04% compared to LivaNova's net margin of 7.48%. TransMedics Group's return on equity of 22.38% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
TransMedics Group	27.04%	22.38%	8.46%

Summary

TransMedics Group beats LivaNova on 12 of the 15 factors compared between the two stocks.

Get TransMedics Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TMDX vs. The Competition

Export

Metric	TransMedics Group	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.66B	$7.30B	$6.66B	$12.19B
Dividend Yield	N/A	1.27%	2.68%	5.89%
P/E Ratio	17.47	49.70	25.35	24.07
Price / Sales	4.39	76.90	588.85	125.28
Price / Cash	18.80	25.22	45.29	53.76
Price / Book	5.58	7.46	10.56	6.37
Net Income	$190.29M	$159.20M	$3.56B	$337.11M
7 Day Performance	-2.42%	0.82%	1.00%	-0.93%
1 Month Performance	11.54%	0.18%	0.80%	0.65%
1 Year Performance	-40.21%	6.07%	31.01%	29.50%

TransMedics Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TMDX TransMedics Group	4.6992 of 5 stars	$76.88 -0.9%	$134.50 +74.9%	-41.5%	$2.66B	$605.49M	17.47	210	Positive News
GKOS Glaukos	2.9204 of 5 stars	$129.27 +1.9%	$148.00 +14.5%	+37.4%	$7.59B	$507.44M	N/A	1,094
LQDA Liquidia	3.2384 of 5 stars	$71.04 -0.3%	$60.29 -15.1%	+448.2%	$6.33B	$158.32M	508.71	50	Analyst Forecast Insider Trade
BLCO Bausch + Lomb	2.3672 of 5 stars	$14.91 -1.1%	$17.92 +20.2%	+29.2%	$5.32B	$5.10B	N/A	13,000
STVN Stevanato Group	2.5837 of 5 stars	€16.81 -1.6%	N/A	-30.6%	€5.10B	€1.20B	28.48	6,010	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TMDX) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransMedics Group (TMDX) Competitors

TMDX vs. GKOS, LQDA, BLCO, STVN, and LIVN

How does TransMedics Group compare to Glaukos?

Summary

How does TransMedics Group compare to Liquidia?

Summary

How does TransMedics Group compare to Bausch + Lomb?

Summary

How does TransMedics Group compare to Stevanato Group?

Summary

How does TransMedics Group compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDX vs. The Competition

TransMedics Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransMedics Group (TMDX) Competitors

TMDX vs. GKOS, LQDA, BLCO, STVN, and LIVN

How does TransMedics Group compare to Glaukos?

Is TMDX or GKOS more profitable?

Do institutionals and insiders have more ownership in TMDX or GKOS?

Does the media favor TMDX or GKOS?

Do analysts recommend TMDX or GKOS?

Which has stronger earnings & valuation, TMDX or GKOS?

Which has more risk & volatility, TMDX or GKOS?

Summary

How does TransMedics Group compare to Liquidia?

Which has more volatility and risk, LQDA or TMDX?

Do analysts rate LQDA or TMDX?

Is LQDA or TMDX more profitable?

Do institutionals & insiders have more ownership in LQDA or TMDX?

Does the media prefer LQDA or TMDX?

Which has better valuation and earnings, LQDA or TMDX?

Summary

How does TransMedics Group compare to Bausch + Lomb?

Do analysts prefer BLCO or TMDX?

Do insiders & institutionals have more ownership in BLCO or TMDX?

Is BLCO or TMDX more profitable?

Does the media prefer BLCO or TMDX?

Which has more risk and volatility, BLCO or TMDX?

Which has preferable earnings & valuation, BLCO or TMDX?

Summary

How does TransMedics Group compare to Stevanato Group?

Which has stronger valuation and earnings, TMDX or STVN?

Does the media prefer TMDX or STVN?

Is TMDX or STVN more profitable?

Do analysts recommend TMDX or STVN?

Do insiders & institutionals have more ownership in TMDX or STVN?

Which has more volatility and risk, TMDX or STVN?

Summary

How does TransMedics Group compare to LivaNova?

Do analysts prefer LIVN or TMDX?

Do insiders & institutionals have more ownership in LIVN or TMDX?

Which has higher valuation & earnings, LIVN or TMDX?

Which has more volatility & risk, LIVN or TMDX?

Does the media favor LIVN or TMDX?

Is LIVN or TMDX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDX vs. The Competition

TransMedics Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools